脂质体伊立替康联合S-1治疗吉西他滨难治性转移性胰腺癌的1/2期研究
本单臂开放标签1/2期研究纳入吉西他滨难治性转移性胰腺癌患者,1期确定脂质体伊立替康70 mg/m2(第1天)联合S-1 80 mg/m2/天(第1-7天)为2期推荐剂量,2期主要终点为总生存期。49例患者接受该剂量治疗,中位总生存期10.3个月(95%CI 8.1-12.0),确认部分缓解10例(20.4%),未发生治疗相关死亡。
要点
- 脂质体伊立替康70 mg/m2(第1天)联合S-1 80 mg/m2/天(第1-7天)为2期推荐剂量
- 49例患者中位总生存期10.3个月(95%CI 8.1-12.0个月)
- 确认部分缓解10例(20.4%),最常见治疗中出现的不良事件为低白蛋白血症(98.0%)、贫血(98.0%)和厌食(81.6%)
核心结论
- 脂质体伊立替康联合S-1在吉西他滨难治性转移性胰腺癌患者中显示出有前景的疗效和可接受的安全性。
研究设计与样本
- 单臂、开放标签的1/2期研究,纳入组织学或细胞学确诊的腺癌、年龄20-80岁、ECOG体能状态0-1、转移性疾病且对吉西他滨为基础的治疗难治的患者。
- 1期部分主要终点为脂质体伊立替康联合S-1的剂量限制性毒性发生频率;2期部分主要终点为总生存期。
- 试验注册于日本临床试验注册数据库(jRCTs031210040)。
主要发现
- 1期部分在脂质体伊立替康70 mg/m2(第1天)联合S-1 80 mg/m2/天(第1-7天)、2周周期方案中观察到1例剂量限制性毒性,确定该剂量为2期推荐剂量。
- 来自1期(n=6)和2期(n=43)的49例患者接受2期推荐剂量治疗,结果合并分析,中位总生存期为10.3个月(95%CI 8.1-12.0个月)。
- 10例患者(20.4%)达到确认的部分缓解。
- 最常见的治疗中出现的不良事件为低白蛋白血症(98.0%)、贫血(98.0%)和厌食(81.6%)。
- 未发生治疗相关死亡。
关键数值与推荐
- 2期推荐剂量为脂质体伊立替康70 mg/m2(第1天)联合S-1 80 mg/m2/天(第1-7天),2周为一周期。
- 中位总生存期10.3个月(95%CI 8.1-12.0个月)。
- 确认部分缓解率20.4%(10例)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Liposomal irinotecan (nal-IRI) plus fluorouracil/folinic acid (5-FU/LV) improves survival in gemcitabine-refractory metastatic pancreatic cancer (PC) but requires a central venous port. S-1, an oral fluoropyrimidine with proven efficacy in PC, may replace 5-FU/LV in nal-IRI plus 5-FU/LV, potentially enhancing both convenience and antitumor effect. METHODS: This single-arm, open-label, phase 1/2 study included patients with histologically or cytologically confirmed adenocarcinoma, aged 20-80 years, an Eastern Cooperative Oncology Group performance status of 0-1, with metastatic disease, and refractory to gemcitabine-based treatment. The primary endpoint in phase 1 part was the frequency of dose-limiting toxicity (DLT) to nal-IRI plus S-1. The primary endpoint in phase 2 part was overall survival. This trial was registered in the Japan Registry of Clinical Trials database (jRCTs031210040). RESULTS: In phase 1 part, one patient with DLT was observed at nal-IRI 70 mg/m2 (day 1) with S-1 80 mg/m2/day (day 1-7) in a 2-week cycle, establishing this as the recommended phase 2 dose (RP2D). Forty-nine patients from phase 1 (n = 6) and phase 2 part (n = 43) were treated with the RP2D, and their results were pooled. Median overall survival was 10.3 months (95 % confidence interval, 8.1-12.0 months). A confirmed partial response was achieved in 10 patients (20.4 %). The most frequent treatment-emergent adverse events were hypoalbuminemia (98.0 %), anemia (98.0 %), and anorexia (81.6 %). There were no treatment-related deaths. CONCLUSIONS: This study demonstrated that nal-IRI plus S-1 exhibited promising efficacy and an acceptable safety profile in patients with metastatic PC refractory to gemcitabine-based treatment.
引用
- Imaoka H, Ikeda M, Ozaka M, et al. Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment. Eur J Cancer. 2025. PMID: 40252631. doi:10.1016/j.ejca.2025.115424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。